From: Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial
Arm A (n = 38)
Arm B (n = 40)
p
Completion rate
73.7% (95% CI: 58.0%–85.0%)
45.0%
(95% CI: 30.7%–60.2%)
0.01
Relative dose intensity
77.2%
(95% CI: 66.8%–87.5%)
58.4%
(95% CI: 47.3%–69.6%)